At present, Denosumab, an FDA-approved monoclonal antibody targeting RANKL, has demonstrated effectiveness in long-term clinical treatment of osteoporosis without increasing the risk of cancer, infection, cardiovascular diseases, delayed fracture healing, or hypocalcemia (Bone et al., 2017). Here, TNFSF11 is linked to osteoporosis.